Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu(Chinese PLA General Hospital), Weiguo Su(Tamedia (Switzerland)), Chunmei Bai(Shanxi Medical University), Zhiwei Zhou(Sun Yat-sen University), Ying Yuan(Zhejiang Cancer Hospital), Shukui Qin(81th Hospital of PLA), Dianrong Xiu(Peking University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Songhua Fan, Ying Cheng(Jilin Province Tumor Hospital), Lin Shen(Peking University), Yihebali Chi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuxian Bai(Harbin Medical University), Mengye Peng, Jing Li(Rutgers, The State University of New Jersey), Xianjun Yu(Fudan University Shanghai Cancer Center), Tao� Zhang(Ningbo University), Wei Wang(Sun Yat-sen University), Jia Chen(Tongji Hospital), Jie Li(Nanjing University of Chinese Medicine), Zhiping Li(Sichuan University), Tianshu Liu(Sun Yat-sen University), Xianglin Yuan(Tongji Hospital), Xiuwen Wang(Second Hospital of Shandong University), Ru Jia(Chinese PLA General Hospital), Min Tao(Shanghai East Hospital), Xingya Li(Zhengzhou University), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University), Nong Xu(First Affiliated Hospital Zhejiang University), Yanhong Deng(Sun Yat-sen University)
The Lancet Oncology
September 20, 2020
10.1016/s1470-2045(20)30496-4
Cited by 193

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k